Location History:
- Ibaraki, JP (2018 - 2022)
- Ibaraki-ken, JP (2022)
- Tokyo, JP (2022)
- Tsukuba-Ibaraki-ken, JP (2022)
- Tsukuba, JP (2018 - 2024)
Company Filing History:
28 out of 273 
8 out of 371 
4 out of 815 
Years Active: 2018-2025
Title: Innovations and Contributions of Nahoko Baileykobayashi
Introduction
Nahoko Baileykobayashi, an inventive mind located in Tsukuba, Japan, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 28 patents, Baileykobayashi's work primarily focuses on innovative therapeutic approaches targeting viral infections and cancer.
Latest Patents
Among his latest patents, Baileykobayashi developed an siRNA based on the RNA sequence of SARS-CoV-2. This invention presents a novel approach to suppressing the proliferation of new coronaviruses. The siRNA consists of a sense strand that incorporates a target sequence comprising 19 to 23 bases with specific terminal requirements and an antisense strand that is complementary to the sense strand. Specifically, the target sequence includes segments that encode a signal peptide region of the spike protein of SARS-CoV-2. In addition, his patent on an antitumor peptide highlights his dedication to addressing cancer, showcasing innovative methodologies in therapeutic peptide design.
Career Highlights
Throughout his career, Baileykobayashi has been associated with esteemed organizations, including Toagosei Company, Ltd. and the National University Corporation Nagoya University. His work in these institutions has fostered a collaborative environment to advance research and innovation.
Collaborations
Collaboration is a key aspect of Baileykobayashi's career. He has worked closely with notable researchers such as Tetsuhiko Yoshida and Makoto Sawada, contributing to a wealth of knowledge in the field. These partnerships have been instrumental in driving forward innovative solutions to contemporary health challenges.
Conclusion
Nahoko Baileykobayashi's contributions to biotechnology, particularly in the development of siRNA therapies and antitumor peptides, underscore his role as a leading inventor in the sector. With a strong foundation in both academia and industry, his work continues to inspire advancements in medical science.